MK-8342B
Total Payments
$917,539
Transactions
595
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $1,149 | 1 | 0 |
| 2018 | $76,182 | 5 | 0 |
| 2017 | $840,208 | 589 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $917,539 | 595 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, single arm, clinical trial to study the contraceptive efficacy and safety of the MK-8342B etonogestrel 17 -estradiol vaginal ring in healthy women 18 years of age and older, at risk for pregnancy | Merck Sharp & Dohme Corporation | $730,920 | 1 |
| An Open-Label, 2-Period Cross-Over Study in Healthy Female Volunteers to Evaluate the Use of Vaginal Antimycotic Suppositories on the Pharmacokinetics of Etonogestrel ENG and Estradiol E2 Released from the ENG-E2 MK-8342B Vaginal Ring | Merck Sharp & Dohme Corporation | $65,957 | 0 |
| A Phase 3 Randomized, Double-blind, Placebo-Controlled Trial to Study the Efficacy and Safety of MK-8342B ENG-E2 vaginal ring in Women with Moderate to Severe Primary Dysmenorrhea. | Merck Sharp & Dohme Corporation | $61,715 | 0 |
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Study the Efficacy and Safety of MK-8342B ENG-E2 Vaginal Ring in Women with Moderate to Severe Primary Dysmenorrhea with Optional Extension. | Merck Sharp & Dohme Corporation | $58,947 | 0 |
Top Doctors Receiving Payments for MK-8342B
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Walnut Creek, CA | $915,039 | 594 |
| Ramon Cestero | — | Colton, CA | $2,500 | 1 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $917,539
Product Information
- Type Drug
- Total Payments $917,539
- Total Doctors 1
- Transactions 595
About MK-8342B
MK-8342B is a drug associated with $917,539 in payments to 1 healthcare providers, recorded across 595 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2019. In 2019, $1,149 was paid across 1 transactions to 0 doctors.
The most common payment nature for MK-8342B is "Unspecified" ($917,539, 100.0% of total).
MK-8342B is associated with 4 research studies, including "A Phase 3, single arm, clinical trial to study the contraceptive efficacy and safety of the MK-8342B etonogestrel 17 -estradiol vaginal ring in healthy women 18 years of age and older, at risk for pregnancy" ($730,920).